- Abivax shares surge as worries subside over immune drug’s cancer risk<figure><div><img src="https://imgproxy.divecdn.com/4eoVQHFTAvljHZA3dtwvKrrS1WlgcrV7_wLUFGcZYWw/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjMwMTMxMDIyXzEua…BioPharma Dive · 26d ago↗ source
- FDA says Zyn can market its pouches as safer than cigarettesThe influence of the alcohol industry on policy, AI Claude for scientists, and more health news from Morning RoundsSTAT · 26d ago↗ source
- STAT+: FDA approves Orca Bio’s T cell therapy for blood cancer patientsThe FDA approved a T-cell therapy from Orca Bio that reduces the risk of a debilitating immune reaction in patients with blood cancers undergoing stem cell transplants.